In this report, I share my key takeaways from the first virtual meeting of the American Society for Gene & Cell Therapy.
After 4 days of virtual seminars, Q&As and science, the first virtual meeting of the American Society of Gene & Cell Therapy (ASGCT; May 12-15) has closed. As I’m sure was the case for many people, I was very disappointed not to be winging my way to Boston; after the challenges of the meeting simply being too big for its venue last year, I was excited to see how the meeting would compare when it had more room to stretch its wings.
However, there were some benefits to the virtual format; a drastically shorter and cheaper travel time, as demonstrated by Despoina Mademtzoglou, could make attending or presenting far more accessible to those with limit budgets, mobility and time.
Looking forward to hearing the latest #geneTherapy and #cellTherapy developments at #ASGCT20, while attending the conference 2020-style:
7h59: leaving Paris for Boston
8h00: arrived at conference site pic.twitter.com/n4MMdakxxd
– Despoina Mademtzoglou (@DMademtzoglou) May 12, 2020
I also enjoying having time to process the talks; watching the talks from the comfort of my own home allowed me to mute sessions or even have another window open to check my understanding of a topic. Whilst I missed being able to duck into talks until I found one I liked, or that had the most excitement in the room, I left talks with a better appreciation of their subjects and without feeling overwhelmed as is sometimes the case (particularly with the sea of people in the poster sessions!).
Thank you, @carlhjune, for discussing your #CART #CellTherapy research and #cancer clinical trials at @Penn, including a #CRISPR-engineered T cell trial, with our #ASGCT20 attendees! pic.twitter.com/hTEUb9heAp
– ASGCT (@ASGCTherapy) May 13, 2020
But what about the science? Presenters certainly didn’t let the virtual format hold them back. Noteworthy talks included a rousing presentation from Carl June (University of Pennsylvania, PA, USA) to Michael Sadelain’s (Memorial Sloan Kettering Cancer Center, NY, USA) fascinating talk on the potential of CAR-T cells against senescence, which could hope promise in treating the effects of aging.
Michel Sadelain dropped a bombshell at #ASGCT20 . CAR-T cells against senescent cells. To be published in a week or two. Exciting!
– Alessio D. Nahmad (@alessionahmad) May 12, 2020
As expected, a key theme of this year’s meeting was focused around expanding manufacturing capacity and ensuring basic research developments were scalable and translatable.
We enjoyed this @US_FDA poster presentation at #ASGCT20 as it tackles a major challenge in scaling up the manufacturing of lentiviral vectors. This #ddPCR assay only takes 8 hrs & correlates closely w/ conventional 72-hr-flow-based titration methods. That’s a 9-fold time-savings! pic.twitter.com/5CyOdUsX9v
– Dropworks (@DropworksInc) May 14, 2020
On the subject of basic research, there was lots of investigation around AAV biology. Potential differences in AAV production has implications in stability, immunogenicity and expression, amongst other things, so a more complete understanding of their intricacies is important.
Color me biased, but @Nicole_Paulk‘s #ASGCT20 award talk was like 2-3 #AAVbiology papers in one. First obs that:
1) #AAV genomes are epigenetically modified
2) #AAV capsids have PTMs
3) Both differ for 293 vs Sf9 production
4) In vivo potency affected, incl. #humanized ðŸ & â™‚ï¸â™€ï¸
– Martin Borch Jensen (@MartinBJensen) May 15, 2020
The format wasn’t perfect, however; in scenes reminiscent of last year’s meeting, where attendees were queuing outside almost every room, the virtual system sometimes struggled to cope with so many people joining at a similar time. I also didn’t attend any of the networking events, so I’d be interested to hear from any attendees how successful ‘virtual’ networking was.
Overall, an enjoyable meeting and a fine example of how the move to virtual can actually improve a meeting. I am feeling a lot more enthusiastic about my next virtual conference and am looking forward to the first published papers.
Want more? Read our ASGCT 2020 abstract highlights:
- Donor sex has no effect on quality of umbilical cord tissue-derived MSCs
- Surgical targeted delivery procedures developed for gene and cell therapy delivery to the central nervous system
- Novel cell culture medium improves ex vivo stem cell expansion
- Novel strategy for generating “off-the-shelf” CAR T-cells that protects against allorejection
- 3DMedNet: Using numerical modelling (CFD) to design and improve a 3D-printed atomizer for the transfection of cells with virus